López-Alvarenga Juan Carlos, Vargas José Antonio, Schneider-Ehrenberg Oliver Paul, Comuzzie Anthony G, González Jorge, Martínez José Luis
Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas, USA.
Gac Med Mex. 2007 Mar-Apr;143(2):109-14.
The etiology, comorbidity, metabolism, and treatment response vary among overweight and obesity types I, II and III individuals. We assessed the association between obesity type with body mass index, waist circumference and tolerance to a daily dose of 15 mg of sibutramine.
A sample of 701 individuals recruited from 47 health centers was analyzed. All subjects received 15 mg of sibutramine daily for 8 weeks. Weight, height, and waist circumference were measured at day 0 and weeks 4 and 8.
Patients in all obesity types lost proportional amounts of weight (p=0.86), but those in type IIl obesity had a smaller reduction in waist circumference than those in types I and 1 (p=0.003). Side effects of sibutramine were rarely observed. Subjects with type III obesity exhibited even fewer side effects.
The lack of association between weight reduction and decreased waist circumference across obesity types could be related to differences in the sympathetic nervous system or to sibutramine biodistribution. Subjects with body mass index greater than 40 Kg/ m(2) required a higher dose of sibutramine in order to loose the same proportion of abdominal fat as those in other types of obesity.
超重及I型、II型和III型肥胖个体的病因、合并症、代谢及治疗反应各不相同。我们评估了肥胖类型与体重指数、腰围以及每日15毫克西布曲明剂量耐受性之间的关联。
对从47个健康中心招募的701名个体的样本进行了分析。所有受试者每天服用15毫克西布曲明，持续8周。在第0天、第4周和第8周测量体重、身高和腰围。
所有肥胖类型的患者体重均按比例减轻（p = 0.86），但III型肥胖患者的腰围减小幅度小于I型和II型肥胖患者（p = 0.003）。很少观察到西布曲明的副作用。III型肥胖受试者出现的副作用更少。
不同肥胖类型之间体重减轻与腰围减小缺乏关联，可能与交感神经系统差异或西布曲明的生物分布有关。体重指数大于40 Kg/m²的受试者需要更高剂量的西布曲明，才能与其他类型肥胖的受试者减少相同比例的腹部脂肪。
